Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 3.6%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price shot up 3.6% during trading on Tuesday . The company traded as high as $8.63 and last traded at $8.62. 24,017 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,468,070 shares. The stock had previously closed at $8.32.

Wall Street Analyst Weigh In

A number of research firms recently commented on AMRX. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Barclays upped their price target on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a report on Friday, September 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Amneal Pharmaceuticals Stock Up 6.5 %

The business’s 50 day moving average is $8.06 and its 200-day moving average is $7.01. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.82 and a current ratio of 1.33. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -15.79 and a beta of 1.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The business had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 EPS for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rothschild Investment LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter worth $26,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter worth $42,000. Atlanta Consulting Group Advisors LLC acquired a new stake in Amneal Pharmaceuticals in the 1st quarter worth $61,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals in the 2nd quarter worth $62,000. Finally, Trexquant Investment LP acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at about $65,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.